The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in PubMed. This abstract is what is used to create the fingerprint of the publication. If any grants are referenced by the publication, they will be listed here as well.
Construction and evaluation of a multistage Mycobacterium tuberculosis subunit vaccine candidate Mtb10.4-HspX.
Hongxia Niu; Lina Hu; Qing Li; Zejiao Da; Bingxiang Wang; Kefeng Tang; Qi Xin; Hongjuan Yu; Ying Zhang; Yong Wang; et al. (Profiled Author: Ying Zhang)
Lanzhou Center for Tuberculosis Research & Institute of Pathogenic Biology, School of Basic Medical Sciences, Lanzhou University, China.
To search for more effective vaccines to enhance the immunogenicity and protective efficacy of Mycobacterium bovis Bacille Calmette-Guerin (BCG) and to control or even eradicate Mycobacterium tuberculosis (M. tuberculosis) in all stages of infection including the persister bacteria, antigens of Mtb10.4 (Rv0288) expressed in replicating bacilli and HspX (also called Acr, Hsp16.3, Rv2031c) highly expressed in dormant bacilli were fused together to construct a multistage fusion protein Mtb10.4-HspX (MH for short) without affinity tag with potential advantage for clinical use. The human T-cell responses to MH were evaluated for its immunogenicity. Furthermore, MH was emulsified in an adjuvant composed of N,N'-dimethyl-N,N'-dioctadecylammonium bromide (DDA) and mycobacterial cord factor trehalose-6,6-dimycolate (TDM) to construct subunit vaccine, whose immunogenicity and potency to boost BCG primed immunity against M. tuberculosis infection were evaluated in mice. The results showed that the fusion protein MH without affinity tag was stably produced in Escherichia coli and was successfully purified by chromatography. MH was strongly recognized by human T cells from TB patients and persons latently infected with M. tuberculosis. In conclusion, MH in adjuvant DDA-TDM generated strong antigen-specific humoral and cell-mediated immunity, and had the capability to enhance BCG-primed immunity and the protective efficacy against M. tuberculosis in mice. These findings suggest that MH in DDA-TDM have the potential to be a good multistage tuberculosis vaccine candidate.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts and related grants with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Yu Luo; Bingxiang Wang; Lina Hu; Hongjuan Yu; Zejiao Da; Wenwen Jiang; Nannan Song; Yaqing Qie; Honghai Wang; Zhijiao Tang; et al.Vaccine 2009;27(44):6179-85.
Nan-nan Song; Bing-xiang Wang; Da-zhong Shi; Lin-feng Fu; Yu Luo; Hong-juan Yu; Shao-bo Han; Lei Jiao; Ya-qing Qie; Hong-hai Wang; et al.Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases 2009;32(7):513-6.
Jiazhen Chen; Sen Wang; Ying Zhang; Xiaodi Su; Jing Wu; Lingyun Shao; Feifei Wang; Shu Zhang; Xinhua Weng; Honghai Wang; et al.BMC infectious diseases 2010;10():273.
Appears in this Publication
Author of this Publication